C10 Pharma completes a Series A financing round

C10 Pharma, a Norwegian biopharmaceutical company focused on developing novel antibiotics, has completed its first financing round, raising USD 1.5 million. The investors in the Series A round are Novo Seed, acting as lead investor, and Sarsia Seed. C10 Pharmas vision is to develop new antibiotics to treat potentially life-threatening bacterial infections. Despite the critical need for more effective antibiotics to combat drug-resistant ‘super-bugs’ the pipeline of new antibiotics under development is alarmingly slim. C10 Pharma´s ambition is to add to this pipeline through innovative,